Company Overview and News

 
Opcom names former Ericsson executive as director

23h thestar.com.my
KUALA LUMPUR: Opcom Holdings Bhd has appointed Magnus Kreuger as independent and non executive director, the company said in a filing with the stock exchange.
0035

 
Opcom eyes role in Tenaga’s broadband venture

2018-09-13 theedgemarkets
SHAH ALAM: Fibre optic cable company Opcom Holdings Bhd intends to take part in Tenaga Nasional Bhd’s (TNB) venture into telecommunications high-speed broadband, as part of the government’s National Connectivity Plan (NCP).
5347 0035 TNABY TNABF

 
Opcom up 2.63% on intent to participate in Tenaga’s NCP plan

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): Fiber optics cable company Opcom Holdings Bhd rose 2.63% this morning after the company said it intends to take part in Tenaga Nasional Bhd’s (TNB) new venture into telecommunications high-speed broadband, as part of the government’s National Connectivity Plan (NCP).
5347 0035 TNABY TNABF

 
Opcom vying to support TNB for National Connectivity Plan

2018-09-12 theedgemarkets
SHAH ALAM (Sept 12): Fiber optics cable company Opcom Holdings Bhd intends to take part in Tenaga Nasional Bhd’s (TNB) new venture into telecommunications high-speed broadband, as part of the government’s National Connectivity Plan (NCP).
5347 0035 TNABY TNABF

 
Opcom’s 1Q net profit up 20.5%

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): Fiber optics cable company Opcom Holdings Bhd's net profit rose 20.5% to RM833,000 in the first quarter ended June 30, 2018 (1QFY19) compared with RM691,000 in the previous year on lower sales, distribution, finance and operating costs.
0035 BSMAF 1818

 
Opcom banks on new business and export to boost revenue after slow Q1

2018-08-24 thestar.com.my
KUALA LUMPUR: Opcom Holdings Bhd is hoping its strategy to expand business activities and export markets will boost future revenue and profit margin after earnings showed a slight improvement in the first quarter.
0035 BSMAF 1818

 
Opcom gapped up but closed weak, says AllianceDBS Research

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 2): AllianceDBS Research said Opcom Holdings Bhd (Opcom) had on Aug 1 gapped up to reach a high of RM1.02 before closing at the day’s low at 96.5 sen (up 2.5 sen or 2.66%).
0035

 
TM says contract to Opcom via open tender prior to GE14 — report

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Tan Sri Mokhzani Mahathir's firm Opcom Holdings Bhd was awarded the Telekom Malaysia Bhd (TM) broadband installation and restoration contract through open tender and had been selected prior to the 14th general election, according to a Malaysiakini report.
4863 0035 MYTEF BSMAF 1818

 
Report: TM says Unifi contract awarded to Mokhzani Mahathir’s firm through open tender

2018-08-01 malaymail
PETALING JAYA, Aug 1 — Telekom Malaysia (TM) said today that the broadband installation and restoration contract awarded to Tan Sri Mokhzani Mahathir’s firm, Opcom Holdings Bhd, was done through open tender, a news portal reported.
4863 0035 MYTEF BSMAF 1818

 
Telekom ordered to submit report on contract awarded to Dr M’s son

2018-08-01 malaymail
KUALA LUMPUR, Aug 1 — Communications and Multimedia Minister Gobind Singh Deo said today he has asked Telekom Malaysia to submit a report on the awarding of a contract to a company of which Tan Sri Mokhzani Tun Mahathir is the chairman.
4863 0035 MYTEF

 
Umno’s Sg Kandis candidate raps Dr M over son’s GLC contract

2018-08-01 malaymail
SHAH ALAM, Aug 1 — Umno leader Datuk Lokman Noor Adam today criticised Tun Dr Mahathir Mohamad, following reports that one of his son’s company’s bagged an RM11.16 million contract from Telekom Malaysia Bhd (TM).
4863 0035 MYTEF

 
KLCI reverses loss, edges up in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI reversed its earlier loss and climbed into positive territory at the midday break today, tracking gains at the regional markets.
HLFBF 7036 7374 5134 GMALY 2852 5029 5347 0035 4715 TNABY 5208 PNAGF 1929 GMALF 1082 ORHLF 6033 7123 5436 4006 PNADF 0026 5819 TNABF

 
Opcom sees better outlook for second half of 2018

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Opcom Holdings Bhd is expecting an increase in demand for fiber optic cables domestically as a result of the Government's call for doubling of broadband speed to Malaysian consumers.
4863 0035 MYTEF

 
Opcom active, rises 7.45% on bagging Telekom contract

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Opcom Holdings Bhd rose 7.45% in active trade this morning after it bagged an RM11.16 million contract from Telekom Malaysia Bhd for Unifi service installation and restoration.
4863 0035 MYTEF

 
KLCI pares loss, attempts to climb higher in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI pared some its loss at mid-morning today and made an attempt to climb higher in line with the gains at most regional markets.
UPBMF 8621 7113 TPGVF BATS 4162 2089 6033 7123 TGLVY 5436 PNADF 5347 0035 0026 5208 TNABY 5819 TNABF PNAGF GEBHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...